An international clinical trial investigating a new treatment for chronic lower back pain has reached a significant milestone, with biotechnology company Mesoblast announcing the full enrolment of 300 patients. The Phase 3 trial is evaluating rexlemestrocel-L, an allogeneic mesenchymal precursor cell (MPC) therapy, for patients suffering from chronic discogenic lower back pain who have not responded adequately to conservative treatments.
Chronic lower back pain is a pervasive health issue globally, and a major cause of disability in the UK. According to NHS data, back pain is one of the most common reasons people visit their GP, affecting millions of adults each year. Discogenic pain, specifically originating from degenerated intervertebral discs, can be particularly debilitating and challenging to manage with existing therapies, which often include physiotherapy, pain medication, and sometimes surgery.
The current trial aims to assess the efficacy and safety of rexlemestrocel-L in reducing pain and improving function. The therapy involves injecting the MPCs directly into the affected spinal disc, with the goal of regenerating damaged tissue and reducing inflammation. Previous studies have shown promising results, indicating a potential long-term benefit for patients who have exhausted other non-surgical options.
Achieving full enrolment is a critical step in the drug development process, allowing the company to proceed with the treatment and follow-up phases. Mesoblast expects to have top-line data from the trial available in the first half of 2027. If the results are positive, it could pave the way for regulatory submissions and potentially introduce a novel approach to treating a condition that significantly impacts quality of life for many.
For the NHS, a successful new therapy could offer an alternative to complex surgical interventions and reduce the long-term burden of chronic pain management. NICE (National Institute for Health and Care Excellence) guidelines continually review evidence for new treatments, and any approved therapy would undergo rigorous assessment to ensure it provides clinical benefits and is cost-effective within the UK healthcare system.